paid access
Intradermal injections of triamcinolone acetonide in Grahama-Little Syndrome treatment — case report
Affiliations- Klinika Dermatologii, Dermatologii Dziecięcej i Onkologicznej Uniwersytetu Medycznego w Łodzi
paid access
Abstract
Graham-Little-Piccardi-Lasseur syndrome (GLPLS) is a rare lichen planopillaris defined by scarring alopecia, loss of pubic and axillary hairs and progressive development of follicular papules located on the whole body. Topical or systemic corticosteroids, cysclosporine or hydroxychlorquina are the treatments usually proposed. We describe the effectiveness of intralesional triamcinolone acetonide in concentration of 8 mg/mL with oral acitretin 10 mg/day combined with topical 0.05% clobetasol propionate ointment in a patient with GLPLS. After 2 months of treatment, reduction of perifollicular erythema and follicular hyperkeratotic papules were observed with no new area of alopecia. We believe that intralesional triamcinolone acetonide could be an effective treatment by limiting the progression of the disease.
Abstract
Graham-Little-Piccardi-Lasseur syndrome (GLPLS) is a rare lichen planopillaris defined by scarring alopecia, loss of pubic and axillary hairs and progressive development of follicular papules located on the whole body. Topical or systemic corticosteroids, cysclosporine or hydroxychlorquina are the treatments usually proposed. We describe the effectiveness of intralesional triamcinolone acetonide in concentration of 8 mg/mL with oral acitretin 10 mg/day combined with topical 0.05% clobetasol propionate ointment in a patient with GLPLS. After 2 months of treatment, reduction of perifollicular erythema and follicular hyperkeratotic papules were observed with no new area of alopecia. We believe that intralesional triamcinolone acetonide could be an effective treatment by limiting the progression of the disease.
Keywords
Graham-Little-Piccardi-Lasseur syndrome; lichen planopilaris; triamcinolone acetonide
Supp./Additional Files (1)
About this articleTitle
Intradermal injections of triamcinolone acetonide in Grahama-Little Syndrome treatment — case report
Journal
Issue
Article type
Case report
Pages
130-133
Published online
2020-12-07
Page views
1123
Article views/downloads
25
DOI
Bibliographic record
Forum Dermatologicum 2020;6(4):130-133.
Keywords
Graham-Little-Piccardi-Lasseur syndrome
lichen planopilaris
triamcinolone acetonide
Authors
Aleksandra Siekierko
Justyna Ceryn
Małgorzata Skibińska
Aleksandra Lesiak
References (5)- Lyakhovitsky A, Amichai B, Sizopoulou C, et al. A case series of 46 patients with lichen planopilaris: Demographics, clinical evaluation, and treatment experience. J Dermatolog Treat. 2015; 26(3): 275–279.
- Errichetti E, Figini M, Croatto M, et al. Therapeutic management of classic lichen planopilaris: a systematic review. Clin Cosmet Investig Dermatol. 2018; 11: 91–102.
- Viglizzo G, Verrini A, Rongioletti F, et al. Familial Lassueur-Graham-Little-Piccardi syndrome. Dermatology. 2004; 208(2): 142–144.
- Vega Gutiérrez J, Miranda-Romero A, Pérez Milán F, et al. Graham Little-Piccardi-Lassueur syndrome associated with androgen insensitivity syndrome (testicular feminization). J Eur Acad Dermatol Venereol. 2004; 18(4): 463–466.
- Rodríguez-Bayona B, Ruchaud S, Rodríguez C, et al. Autoantibodies against the chromosomal passenger protein INCENP found in a patient with Graham Little-Piccardi-Lassueur syndrome. J Autoimmune Dis. 2007; 4: 1.
